[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiac-magnetic-resonance-imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiac-magnetic-resonance-imaging":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,78,110,133,160,182,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645124","association-between-4d-mri-parameters-and-the-clinical-characteristics-and-prognosis-of-major-chronic-diseases-100645124",false,"NCT07678606","Association Between 4D MRI Parameters and the Clinical Characteristics and Prognosis of Major Chronic Diseases","4D-MRI","Inclusion Criteria:\n\n* Adults aged 19 years and older undergoing clinically indicated Cardiac MRI at Ulsan University Hospital\n* Participants who undergo an additional 4D MRI sequence during the same imaging session\n* Participants who are able to understand the study and provide written informed consent\n\nExclusion Criteria:\n\n* Individuals aged \\\u003C 19 years\n* Individuals with cognitive impairment or communication difficulties unable to provide informed consent\n* Poor-quality MRI images that are not suitable for analysis\n* Individuals deemed inappropriate for study participation by the investigator",true,"ALL","19 Years",{"count":20,"type":21},1000,"ESTIMATED","10 Years","OBSERVATIONAL","Cancer and cardiovascular diseases are among the leading causes of morbidity and mortality worldwide. Advanced imaging techniques such as 4D magnetic resonance imaging (MRI) enable quantitative assessment of hemodynamic and functional parameters beyond conventional imaging. The aim of this study is to evaluate the association between 4D MRI derived parameters and the occurrence, severity, and prognosis of major chronic diseases, and to explore their potential role as imaging biomarkers.",[26,27,28],"Cardiovascular Disease","Cardiac Magnetic Resonance Imaging","Neoplasm",[30,31,27,32],"Cardiovascular disease","Malignancy","Hemodynamic parameters","NOT_YET_RECRUITING","2026-06-24",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":36,"type":21},{"date":40,"type":21},"2046-02-28",{"name":42,"class":43},"Ulsan University Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100581757","the-multicenter-stress-cardiac-magnetic-resonance-quantitative-perfusion-imaging-in-the-united-states-study-100581757","NCT06854458","The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study","The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study","SPINS2","Inclusion Criteria:\n\n1. male or female at age 35-85 years,\n2. presence of either of the following sign\u002Fsymptom that led to a referral to stress cardiac magnetic resonance imaging:\n\n   1. chest pain or anginal equivalent, or\n   2. abnormal electrocardiogram with a suspicion of coronary artery disease\n3. Intermediate or high risk of significant coronary disease based on at least 1 of the following conditions:\n\n   a) patient age \\> 45 for male, 50 for female b) Diabetes, hypertension, or hypercholesterolemia: by either history or medical treatment c) family history of premature coronary disease: first degree relative at age \\\u003C= 55 male and \\\u003C=65 female d) history of smoking of \\> 10 packed-years e) post-menopausal state \\>5 years f) any chronic inflammatory conditions d) Body mass index \\> 30 e) Any medical documentation of coronary or peripheral artery disease\n\nExclusion Criteria:\n\n1. Acute myocardial infarction within the past 30 days prior to cardiac magnetic resonance imaging\n2. Confirmed diagnosis of any significant non-coronary cardiac conditions below:\n\n   1. any severe-grade valvular heart disease,\n   2. left ventricular ejection fraction \\\u003C40% from any known non-coronary causes,\n   3. infiltrative cardiomyopathy,\n   4. hypertrophic cardiomyopathy,\n   5. pericardial disease with significant constriction, or\n3. active pregnancy,\n4. any competing conditions leading to an expected survival of \\\u003C 2 years\n5. contraindication to vasodilator (regadenoson or adenosine)\n6. metallic device or object that poses an magnetic resonance imaging safety hazard\n7. metallic device with a high likelihood of non-diagnostic cardiac magnetic resonance images","35 Years","85 Years",{"count":20,"type":21},"INTERVENTIONAL",[58],"NA","This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.",[61,27,62],"Ischemic Heart Disease (IHD)","Myocardial Blood Flow",[62,64,65,66],"Cardiac Magnetic Resonance","Quantitative perfusion","Cardiovascular Outcomes","RECRUITING","2026-06-01",{"date":70,"type":37},"2026-06-03",{"date":72,"type":37},"2025-06-27",{"date":74,"type":21},"2029-03",{"name":76,"class":43},"Brigham and Women's Hospital",12,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":56,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":44},"100636282","fapi-petct-imaging-in-arrhythmogenic-right-ventricular-cardiomyopathy-arvc-fapi-arvc-100636282","NCT07563660","FAPI PET\u002FCT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))","Incremental Diagnostic and Prognostic Value of 68Ga-DOTA-SA-FAPI PET\u002FCT Imaging in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)","FAPI-ARVC","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Established diagnosis of arrhythmogenic right ventricular cardiomyopathy according to the 2010 Revised Task Force Criteria and\u002For the Padua criteria\n* Under active follow-up at the study center\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* History of malignancy\n* Severe renal impairment\n* Severe hepatic impairment\n* Pregnancy or breastfeeding\n* Prior 68Ga-DOTA-SA-FAPI PET\u002FCT imaging\n* Inability or unwillingness to provide written informed consent\n* Any medical, clinical, or logistical condition that, in the opinion of the investigators, could interfere with study participation, image interpretation, or completion of follow-up","18 Years",{"count":88,"type":21},15,[58],"Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease associated with fibrofatty myocardial replacement, ventricular arrhythmias, and an increased risk of sudden cardiac death. Although current diagnostic approaches, including the 2010 Task Force Criteria and the Padua criteria, improve recognition of the disease, early diagnosis remains challenging, particularly when structural abnormalities are subtle or absent on conventional imaging. Echocardiography and cardiac magnetic resonance imaging are central to evaluation, but their sensitivity for early or active fibrotic remodeling may be limited. This limitation may be particularly relevant in patients who are unable to undergo cardiac magnetic resonance imaging, in whom 68Ga-DOTA-SA-FAPI PET\u002FCT may provide complementary diagnostic information.\n\nThis prospective single-group diagnostic imaging study aims to investigate the incremental value of protocol-specified 68Ga-DOTA-SA-FAPI PET\u002FCT imaging in patients with ARVC. FAPI PET\u002FCT is a novel molecular imaging method that targets activated fibroblasts and may allow non-invasive detection of active myocardial fibrosis.Fifteen adult patients with an established diagnosis of ARVC will undergo protocol-specified 68Ga-DOTA-SA-FAPI PET\u002FCT imaging in addition to clinical evaluation, electrocardiography, echocardiography, and review of previously obtained cardiac magnetic resonance imaging findings. FAPI PET\u002FCT findings will be compared with conventional diagnostic criteria and other clinical and imaging parameters, including previously available cardiac magnetic resonance imaging findings. Participants will also be followed clinically for 6 months after imaging to explore possible associations between FAPI uptake and short-term clinical outcomes, including arrhythmic events, ventricular function, and laboratory markers.\n\nThe study is expected to provide preliminary evidence on whether 68Ga-DOTA-SA-FAPI PET\u002FCT may improve the detection of myocardial fibrosis and contribute to diagnostic assessment and risk stratification in ARVC. It may also help clarify the potential role of FAPI PET\u002FCT in patients who are unable to undergo cardiac magnetic resonance imaging. The findings may support future larger prospective studies in this field.",[92,93,27],"Arrhythmogenic Right Ventricular Cardiomyopathy","FAPI PET",[92,95,96,97,98,99,27,100],"Fibroblast Activation Protein","Positron Emission Tomography Computed Tomography","Molecular Cardiac Imaging","Sudden Cardiac Death Risk Stratification","Inherited Cardiomyopathy","Myocardial Fibrosis","2026-04-30",{"date":103,"type":37},"2026-05-04",{"date":105,"type":37},"2025-04-16",{"date":107,"type":21},"2026-10-26",{"name":109,"class":43},"Istanbul University - Cerrahpasa",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100622323","myocardial-perfusion-cmr-for-differentiating-and-characterizing-hypertrophic-cardiomyopathy-phenotypes-100622323","NCT07382128","Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes","MyoPerf-HCM","Inclusion Criteria:\n\n* A confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype, according to current ESC guidelines; or a first-degree relative of a patient with a confirmed diagnosis of cardiomyopathy with a hypertrophic phenotype; or a carrier of a genetic mutation for hypertrophic cardiomyopathy (carriers).\n* Patient with an indication to undergo cardiac magnetic resonance imaging (CMR) according to current ESC guidelines.\n* Age ≥ 18 years\n* Written informed consent obtained\n\nExclusion Criteria:\n\n\\- History of previous myocardial infarction or myocardial revascularization (coronary artery bypass grafting or percutaneous coronary angioplasty) and\u002For evidence of coronary stenosis ≥ 50% on coronary CT scan or invasive coronary angiography.",{"count":118,"type":21},250,"This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease (AFD), and cardiac amyloidosis. The study will also include first-degree relatives of affected patients and genetic mutation carriers. By comparing myocardial blood flow and perfusion patterns across these different conditions, the study seeks to identify distinctive perfusion signatures that may improve diagnostic differentiation, support risk stratification, and provide insights into the role of ischemia in fibrosis progression, arrhythmias, and long-term outcomes.",[121,122,27,123],"HCM - Hypertrophic Cardiomyopathy","Anderson Fabry Disease","Amyloid Cardiomyopathy","2026-01-26",{"date":126,"type":37},"2026-02-02",{"date":128,"type":37},"2025-06-01",{"date":130,"type":21},"2027-06-01",{"name":132,"class":43},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":56,"phases":143,"briefSummary":144,"conditions":145,"keywords":150,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":44},"100597694","evaluation-of-left-ventricular-ejection-fraction-using-an-accelerated-cardiac-cine-mri-sequence-with-deep-learning-based-image-reconstructions-100597694","NCT07061821","Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions","Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions Compared to the Reference Cine-MRI Sequence in the Assessment or Follow-up of Left Ventricular Hypertrophy","HVGLD","Inclusion Criteria:\n\n* Patient referred for cardiac MRI as part of the assessment or follow-up of left ventricular hypertrophy\n* Age ≥ 18 years old\n* Ability of the subject to understand and express his consent\n* Affiliation to the social security scheme\n\nExclusion Criteria:\n\n* Severe obesity (\\>140 kg) preventing the patient from entering the scanner bore, which has a diameter of less than 70 cm\n* Age ≥ 18 years old\n* Person under guardianship or curators, or deprived of liberty\n* Pregnant or breastfeeding woman\n* Known allergy to gadolinium chelates\n* Claustrophobia\n* Any contraindication to MRI\n* Arrhythmia\n* Inability to hold breath for more than 10 seconds",{"count":142,"type":21},61,[58],"Left ventricular hypertrophy (LVH) is a common condition that may result from hypertension, hypertrophic cardiomyopathy, aortic valve stenosis, or certain metabolic disorders. Cardiac imaging is essential for diagnosis, prognostic assessment, and quantification of cardiac function. While transthoracic echocardiography remains widely used, it is limited by acoustic window dependence and inter-observer variability. Cardiovascular Magnetic Resonance (CMR) imaging currently serves as the reference standard for measuring left ventricular ejection fraction (LVEF), cardiac volumes, and tissue characterization. However, conventional cine-CMR sequences require repeated breath-holds, which are often challenging for elderly or dyspneic patients, generating respiratory motion artifacts that compromise image quality. Accelerated cine-CMR sequences with deep learning-based image reconstructions offer a promising alternative by significantly reducing acquisition time while preserving image quality. This study aims to evaluate whether these accelerated cine-CMR sequences provide LVEF measurements concordant with conventional cine-CMR sequences, with potential to improve patient comfort and reduce examination time.",[146,27,147,148,149],"Left Ventricular Ejection Fraction","Deep Learning","Image Reconstruction","Left Ventricular Hypertrophy",[149,146,27,147,148],"2026-01-15",{"date":153,"type":37},"2026-01-16",{"date":155,"type":37},"2025-08-05",{"date":157,"type":21},"2026-09",{"name":159,"class":43},"Centre Hospitalier Universitaire, Amiens",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":44},"100602968","multimodal-imaging-assessment-after-revascularization-in-patients-with-acute-myocardial-infarction-100602968","NCT07130409","Multimodal Imaging Assessment After Revascularization in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Patients with a clinical diagnosis of first-episode acute myocardial infarction (AMI) who underwent emergency percutaneous coronary intervention (PCI) were included. All patients had complete baseline clinical data, with baseline cardiac magnetic resonance (CMR) examinations performed within 7 days post-PCI and follow-up CMR completed at 6 months post-procedure.\n\nExclusion Criteria:\n\n* Patients with severe cardiac decompensation (Killip class 4) or clinically unstable conditions.\n\nPatients with coexisting valvular heart disease, congenital heart disease, pulmonary hypertension, cardiomyopathy, or persistent atrial fibrillation that may confound cardiac structural\u002Ffunctional assessments.\n\nPrior history of myocardial infarction, coronary revascularization (PCI\u002FCABG).\n\nConcurrent severe systemic diseases including hematologic disorders, malignancies, rheumatic\u002Fautoimmune diseases, or severe hepatic\u002Frenal failure.\n\nContraindications to CMR (claustrophobia, pacemaker implantation, etc.).\n\nPregnant, breastfeeding, or women of childbearing potential without effective contraception.\n\nSexually active individuals of reproductive age unwilling to use reliable contraception.","80 Years",{"count":168,"type":21},20,"This prospective cohort study will enroll 20 patients clinically diagnosed with first-time acute myocardial infarction (AMI) who underwent interventional procedures (including percutaneous coronary intervention \\[PCI\\] and balloon angioplasty) at the Affiliated Hospital of Qingdao University. Patient data, including routine blood and urine tests, blood biochemistry, electrocardiograms (ECG), imaging studies, and interventional procedure records, will be collected to assess eligibility for enrollment. The study procedures include patient screening and enrollment, obtaining informed consent, baseline assessment (including medical history, laboratory tests, ECG, etc.), an ¹⁸F-Pentixafor PET\u002FMR examination, and follow-up. Images will be blindly assessed by at least two specialized physicians from the Radiology and Nuclear Medicine departments. The study aims to investigate the utility of ¹⁸F-Pentixafor PET\u002FMR in evaluating coronary microcirculatory function, cardiac function, myocardial viability, myocardial inflammatory response, and the efficacy of interventional therapy in AMI patients post-procedure. Additionally, it will perform risk stratification and prognostic analysis for the enrolled patients.",[27,171,172],"Acute Myocardial Infarction (AMI)","PET \u002F MR","2025-08-15",{"date":175,"type":37},"2025-08-19",{"date":177,"type":21},"2025-08",{"date":179,"type":21},"2026-12-31",{"name":181,"class":43},"The Affiliated Hospital of Qingdao University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":191,"conditions":192,"keywords":198,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":44},"100577703","when-do-we-have-to-perform-cardiac-magnetic-resonance-in-patients-referred-for-premature-ventricular-complexes-by-their-cardiologists-100577703","NCT06801743","WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS","IRMESV","Inclusion Criteria:\n\n* patients with PVC who have performed ECG, Holter ECG and a CMR\n\nExclusion Criteria:\n\n* patient showing opposition tu use his personal data for the reseach,\n* patient unable to express his opposition,\n* patient deprived of liberty,\n* patient with language issues (speaking or writing French)",{"count":190,"type":21},200,"Premature ventricular complexes (PVC) are a common entity affecting approximatively 20% of the general population. It can be discovered incidentally on electrocardiogram (ECG) or associated with symptoms with a wide spectrum from palpitations, chest pain, to syncope.\n\nThe initial and non invasive assessment includes holter ECG monitoring, a transthoracic echocardiography (TTE) and an exercise stress test to rule out structural heart disease (SHD), and referred to as benign or \"idiopathic\" ventricular arrhythmias (IVA).\n\nHowever, these exams may fail to identify subtle myocardial abnormalities such as arrhythmogenic right ventricle dysplasia (ARVD), apical hypertrophic cardiomyopathy, healed myocarditis, ischemic or non-ischemic cardiomyopathies.\n\nCardiac magnetic resonance (CMR) imaging is the gold standard modality to assess regional and global ventricular function. It is also a unique modality to non-invasively detect myocardial edema, myocardial fatty replacement, focal and diffuse fibrosis and could potentially identify SHD in patients with PVC.\n\nHowever, the role of CMR is uncertain, recommended in case of atypical presentation or when the initial assessment can't exclude a cardiomyopathy (recommendations class IIa).\n\nThis study sought to determine whether and when CMR can be performed to provide diagnosis or prognostic information complementary to initial assessment in patients referred for PVC by their cardiologists.",[193,194,27,195,196,197],"Premature Ventricular Complexes","Ventricular Arythmias","Focal or Diffuse Fibrosis","Structural Heart Disease","Idiopathic",[199,200,201,202,203,204],"premature ventricular complexes","ventricular arythmias","cardiac magnetic resonance","focal or diffuse fibrosis","structural heart disease","idiopathic","2025-02-11",{"date":207,"type":37},"2025-02-13",{"date":209,"type":37},"2024-11-27",{"date":211,"type":21},"2026-05",{"name":159,"class":43},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":221,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":224,"conditions":225,"keywords":242,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":260},"100578603","characterization-of-patients-with-cardiomyopathy-to-identify-critical-patients-candidates-for-cardiac-transplantation-100578603","NCT06813443","Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","Clinical, Instrumental, and Molecular (Circulating and Tissue microRNAs) Characterization of Patients With Cardiomyopathy to Identify Critical Patients With Severe Organ Failure to be Candidates for Cardiac Transplantation","CMPMIRNA","Inclusion Criteria:\n\n* Patients diagnosed with CMP according to current international guidelines\n* Age ≥ 12 years at the time of diagnosis\n* Obtaining informed consent from the patient and the parent or legal guardian (in the case of patients aged \\\u003C 18 years)\n\nExclusion Criteria:\n\n* none","12 Years",{"count":223,"type":21},700,"The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging techniques that may provide insights into the underlying disease mechanisms. By understanding these markers, the investigators hope to improve the way the investigators diagnose and manage CMP, particularly in terms of predicting progression to heart failure or heart transplantation.\n\nThe study will evaluate patients with hypertrophic cardiomyopathy (e.g., sarcomeric forms, Anderson-Fabry disease, AL, and TTR cardiac amyloidosis), dilated cardiomyopathy and arrhythmogenic cardiomyopathy. These patients will undergo clinical evaluations, including ECG, echocardiograms, CMR, biopsy analysis, and genetic testing, as well as molecular studies such as transcriptomics and miRNA analysis. This comprehensive approach aims to identify potential new biomarkers for diagnosing and predicting the disease course.",[226,227,228,229,230,231,232,233,234,235,236,237,238,27,239,240,241],"Cardiomyopathies","Amyloidosis Cardiac","Fabry Disease","Arrhythmogenic Cardiomyopathy","Hypertrophic Cardiomyopathy (HCM)","Laminopathies","Dystrophia Myotonica","Mitochondrial Cardiomyopathy","Dilated Cardiomyopathy","Sudden Cardiac Death","Heart Transplantation","Glycogen Storage Disease","Infiltrative Cardiomyopathy","Electrocardiogram","Micro RNA","Echocardiogram",[243,244,245,246,247,248,249,250,251],"cardiomyopathy","cardiac amyloidosis","Fabry disease","hypertrophic cardiomyopathy","dilated cardiomyopathy","sudden cardiac death","arrhythmogenic cardiomyopathy","heart failure","heart transplantation","2025-02-03",{"date":254,"type":37},"2025-02-07",{"date":256,"type":37},"2023-02-13",{"date":258,"type":21},"2027-12-14",{"name":132,"class":43},3]